Learn More
PURPOSE We performed a retrospective analysis to assess the durability of benefit derived from irradiation after prostatectomy for pT3N0 disease, and the possibility of cure. METHODS AND MATERIALS We studied 88 patients who were irradiated after prostatectomy and had available prostate specific antigen (PSA) data, no known nodal or metastatic disease, no(More)
PURPOSE This study assessed the ability of nadir prostate-specific antigen (PSA) to act as an early surrogate for subsequent freedom from biochemical failure following radiation therapy for T1-2 prostatic adenocarcinoma. METHODS AND MATERIALS A retrospective analysis was performed on the biochemical outcome of 314 consecutive men with T1-2 disease treated(More)
OBJECTIVES In the United States, radical retropubic prostatectomy for adenocarcinoma usually includes a staging pelvic lymphadenectomy. If frozen section analysis of the lymph nodes fails to reveal any evidence of metastases, the prostate is removed. We have previously noted that as many as 56% of patients undergoing radical prostatectomy demonstrate rising(More)
PURPOSE To assess the long-term outcome of conventional external beam radiation therapy in the management of clinically confined prostate cancer and to examine the proposition that radiation accelerates tumor growth in those who fail treatment. METHODS AND MATERIALS One thousand and forty-four men with T1-4NxM0 prostate cancer treated by conventional(More)
OBJECTIVES The most relevant endpoint in comparing the efficacy of curative therapies for prostate cancer is cancer-specific death. Prospective trials need to mature for a least a decade to yield meaningful cancer death data due to the long natural history of the disease amd the use of salvage androgen suppression. This delay may be long enough that the(More)
  • 1